5 Years’ Experience of Ixcellence Network®, an International Innovative Educational Program to improve Cervical Dystonia and Spastic paresis Management Practices
Objective: To describe the impact of the Ixcellence® Network training program on physicians using botulinum neurotoxin-A (BoNT-A) in cervical dystonia (CD) and spastic paresis (SP).…First Results from the Ixcellence Network® Survey: Botulinum Neurotoxin-A Usage and Training in Cervical Dystonia & Spastic Paresis
Objective: To describe the current situation of training and practices among physicians using botulinum neurotoxin-A (BoNT-A) injections in the treatment of Cervical Dystonia (CD) and…“Appropriate Doses Treatment” of IncobotulinumtoxinA in spasticity
Objective: The aim of this study is to object the efficiency and safety of 100 to 1000 units botulinum toxin treatment with modulation of spasticity…Evaluation of Effectiveness and Safety of Botulinum Toxin Type-A (BTX-A) for Chronic Focal Post-Stroke Upper Limb Spasticity in Indian Stroke Patients
Objective: To evaluate the effectiveness and safety of Botulinum Toxin Type-A (BTX-A) for the treatment chronic focal post-stroke upper limb spasticity in Indian stroke patients.…Efficacy of IncobotulinumtoxinA in Treatment of Lower Limb Spasticity in Adults
Objective: To evaluate the effectiveness of incobotulinumtoxinA for treating key clinical patterns of lower limb (LL) spasticity (eg, pes equinovarus) using a post-hoc analysis. Background:…Efficacy of IncobotulinumtoxinA for the Treatment Of Shoulder Spasticity
Objective: To evaluate efficacy of botulinum toxin for shoulder spasticity using a post-hoc analysis. Background: Botulinum toxin has been shown to be effective for treating…Effect of early AbobotulinumtoxinA (Dysport®) use after stroke on the time to reach reinjection criteria: asymptomatic versus symptomatic patients
Objective: To determine if early post-stroke (within 12 weeks) abobotulinumtoxinA (aboBoNT-A;Dysport®) injections delay appearance or progression of upper limb symptomatic spasticity. Background: Muscle tone changes…Time to retreatment with botulinum toxin A in upper limb spasticity management: initial data from the Upper Limb International Spasticity (ULIS)-III study
Objective: The ongoing ULIS-III study aims to describe real-life clinical practice and assess patient‑centered goal attainment with integrated upper limb spasticity (ULS) management that includes…Epidemiological profile and challenges of a reference public center for the treatment of neurological conditions using botulinum toxin type A: experience of a North-eastern center in Brazil.
Objective: To identify the epidemiological profile of patients treated with botulinum toxin type A (BTA) in a tertiary clinic in Brazil. Background: BTA is used to…A Comparison of Muscular Atrophy Between Botulinum Toxin Types A and B
Objective: To compare and quantify the degree of muscular atrophy (MA) in botulinum toxin (BT) type A (Botox) and type B (Myobloc). A secondary endpoint…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- Next Page »